AFT Pharmaceuticals Limited (NZX: AFT) AFT welcomes Australian Federal Court appeal success

Thursday 9th December 2021

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today welcomes the Australian Federal Court’s decision this week to allow its appeal of a comparative advertising judgement brought by Reckitt Benckiser.

The Australian Federal Court has found AFT was justified in making a series of claims in relation to the efficacy of its Maxigesic pain relief tablets in comparison to Ibuprofen alone or paracetamol alone.

Reckitt Benckiser has until 4 January 2022 to file an application for special leave to appeal to the High Court should it so chose. We are therefore unable to make further comment at this time.

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.

Please see the link below for details

AFT welcomes Australian Federal Court appeal success

Source: AFT Pharmaceuticals Limited

Comments from our readers

No comments yet